HRP20050707B1 - Polimorf od {6,7-bis(2-metoksi-etoksi)-kinazolin-4-il}-(3e) - Google Patents
Polimorf od {6,7-bis(2-metoksi-etoksi)-kinazolin-4-il}-(3e)Info
- Publication number
- HRP20050707B1 HRP20050707B1 HRP20050707AA HRP20050707A HRP20050707B1 HR P20050707 B1 HRP20050707 B1 HR P20050707B1 HR P20050707A A HRP20050707A A HR P20050707AA HR P20050707 A HRP20050707 A HR P20050707A HR P20050707 B1 HRP20050707 B1 HR P20050707B1
- Authority
- HR
- Croatia
- Prior art keywords
- quinazolin
- ethoxy
- methoxy
- bis
- polymorph
- Prior art date
Links
- -1 2-methoxy-ethoxy Chemical group 0.000 title 1
- GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Izum se odnosi na novi polimorf od [6,7-Bis(2-metoksi-etoksi)-kinazolin-4 il]-(3-etinil-fenil)amin hidroklorida. Ovaj polimorf pokazuje superiornija svojstva u usporedbi sa prije poznatim oblicima od [6,7-Bis(2-metoksi-etoksi)-kinazolin-4 il]-(3-etinil-fenil)amin hidroklorida i može se upotrijebiti za liječenje hiperproliferacijskih bolesti.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03003587 | 2003-02-17 | ||
PCT/EP2004/001244 WO2004072049A1 (en) | 2003-02-17 | 2004-02-11 | Polymorph of {6,7-bis(2-methoxy-ethoxy)-quinazolin-4-yl}-(3e) |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20050707A2 HRP20050707A2 (en) | 2006-07-31 |
HRP20050707B1 true HRP20050707B1 (hr) | 2013-10-25 |
Family
ID=32842701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20050707AA HRP20050707B1 (hr) | 2003-02-17 | 2005-08-10 | Polimorf od {6,7-bis(2-metoksi-etoksi)-kinazolin-4-il}-(3e) |
Country Status (24)
Country | Link |
---|---|
US (1) | US7148231B2 (hr) |
EP (1) | EP1597239B2 (hr) |
JP (1) | JP4456079B2 (hr) |
KR (1) | KR100797430B1 (hr) |
CN (1) | CN100506803C (hr) |
AT (1) | ATE408605T1 (hr) |
AU (1) | AU2004212067C1 (hr) |
BR (1) | BRPI0407520A (hr) |
CA (1) | CA2514977C (hr) |
CO (1) | CO5601019A2 (hr) |
DE (1) | DE602004016628D1 (hr) |
DK (1) | DK1597239T4 (hr) |
ES (1) | ES2314373T5 (hr) |
HR (1) | HRP20050707B1 (hr) |
IL (1) | IL169975A (hr) |
MX (1) | MXPA05008598A (hr) |
NO (1) | NO330781B1 (hr) |
NZ (1) | NZ541500A (hr) |
PL (1) | PL225428B1 (hr) |
PT (1) | PT1597239E (hr) |
RU (1) | RU2376294C2 (hr) |
SI (1) | SI1597239T2 (hr) |
WO (1) | WO2004072049A1 (hr) |
ZA (1) | ZA200506339B (hr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US7625911B2 (en) * | 2005-01-12 | 2009-12-01 | Mai De Ltd. | Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion |
SI2032521T1 (sl) | 2006-06-27 | 2010-02-26 | Sandoz Ag | Nov postopek za pripravo soli |
CN101547910A (zh) | 2006-07-28 | 2009-09-30 | 合成纤维有限公司 | 结晶埃罗替尼 |
US8372856B2 (en) | 2006-10-27 | 2013-02-12 | Synthon Bv | Hydrates of erlotinib hydrochloride |
PT2170844T (pt) | 2007-02-21 | 2016-08-05 | Natco Pharma Ltd | Novos polimorfos de cloridrato de erlotinib e método de preparação |
KR101441930B1 (ko) * | 2007-04-04 | 2014-09-19 | 시플라 리미티드 | 에르로티닙 및 그의 약학적으로 허용가능한 염의 제조방법 |
EP2218713A1 (en) | 2007-08-17 | 2010-08-18 | Hetero Drugs Limited | Erlotinib hydrochloride polymorph Form A substantially free of polymorph Form B |
US20090124642A1 (en) * | 2007-08-23 | 2009-05-14 | Augusto Canavesi | Crystalline forms of Erlotinib HCI and formulations thereof |
US20090131665A1 (en) * | 2007-08-23 | 2009-05-21 | Ales Gavenda | Process for the preparation of crystalline forms A, B and pure crystalline form a of erlotinib HCI |
WO2010005924A1 (en) * | 2008-07-07 | 2010-01-14 | Plus Chemicals Sa | Crystalline forms of erlotinib base and erlotinib hcl |
WO2010040212A1 (en) * | 2008-10-08 | 2010-04-15 | Apotex Pharmachem Inc. | Processes for the preparation of erlotinib hydrochloride |
EP2213281A1 (en) | 2009-02-02 | 2010-08-04 | Ratiopharm GmbH | Pharmaceutical composition comprising N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
US8440823B2 (en) | 2009-03-26 | 2013-05-14 | Ranbaxy Laboratories Limited | Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof |
WO2011058525A2 (en) | 2009-11-12 | 2011-05-19 | Ranbaxy Laboratories Limited | Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b |
CN101987834B (zh) * | 2010-06-13 | 2012-07-18 | 信泰制药(苏州)有限公司 | 一种结晶形态的盐酸埃罗替尼及其制备方法 |
US8952022B2 (en) | 2010-07-23 | 2015-02-10 | Generics [Uk] Limited | Pure erlotinib |
US20140121373A1 (en) | 2011-05-03 | 2014-05-01 | Cadila Healthcare Limited | Process for preparing stable polymorphic form of erlotinib hydrochloride |
WO2014037961A1 (en) | 2012-09-04 | 2014-03-13 | Shilpa Medicare Limited | Crystalline erlotinib hydrochloride process |
WO2014118737A1 (en) | 2013-01-31 | 2014-08-07 | Ranbaxy Laboratories Limited | Erlotinib salts |
CN103333124B (zh) * | 2013-05-28 | 2015-03-25 | 埃斯特维华义制药有限公司 | 一种制备盐酸厄洛替尼晶型f的方法 |
WO2016082879A1 (en) * | 2014-11-27 | 2016-06-02 | Synthon B.V. | Pharmaceutical composition comprising erlotinib hydrochloride |
RU2610337C1 (ru) * | 2015-12-10 | 2017-02-09 | Индивидуальный предприниматель Михайлов Олег Ростиславович | Кристаллическая β-модификация N-(3-этинилфенил)-6,7-бис(2 метоксиэтокси)хиназолин-4-амин гидрохлорида, способ её получения и фармацевтическая композиция на её основе |
JP2019059685A (ja) * | 2017-09-26 | 2019-04-18 | 日本化薬株式会社 | エルロチニブを有効成分とする医薬錠剤 |
JP2020090456A (ja) * | 2018-12-05 | 2020-06-11 | 日本化薬株式会社 | エルロチニブを有効成分とする医薬錠剤 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996030347A1 (en) * | 1995-03-30 | 1996-10-03 | Pfizer Inc. | Quinazoline derivatives |
WO1999055683A1 (en) * | 1998-04-29 | 1999-11-04 | Pfizer Products Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
EP1044969A2 (en) * | 1999-03-31 | 2000-10-18 | Pfizer Products Inc. | Processes and intermediates for preparing anti-cancer compounds |
WO2001034574A1 (en) * | 1999-11-11 | 2001-05-17 | Osi Pharmaceuticals, Inc. | Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6434574A (en) * | 1987-07-30 | 1989-02-06 | Mazda Motor | Full mold casting device |
US5747498A (en) † | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
-
2004
- 2004-02-03 US US10/771,217 patent/US7148231B2/en not_active Expired - Lifetime
- 2004-02-11 CA CA2514977A patent/CA2514977C/en not_active Expired - Lifetime
- 2004-02-11 SI SI200430902T patent/SI1597239T2/sl unknown
- 2004-02-11 AU AU2004212067A patent/AU2004212067C1/en not_active Expired
- 2004-02-11 NZ NZ541500A patent/NZ541500A/en not_active IP Right Cessation
- 2004-02-11 MX MXPA05008598A patent/MXPA05008598A/es active IP Right Grant
- 2004-02-11 KR KR1020057015068A patent/KR100797430B1/ko active IP Right Grant
- 2004-02-11 EP EP04710031.8A patent/EP1597239B2/en not_active Expired - Lifetime
- 2004-02-11 DE DE602004016628T patent/DE602004016628D1/de not_active Expired - Lifetime
- 2004-02-11 WO PCT/EP2004/001244 patent/WO2004072049A1/en active IP Right Grant
- 2004-02-11 ES ES04710031T patent/ES2314373T5/es not_active Expired - Lifetime
- 2004-02-11 PL PL378561A patent/PL225428B1/pl unknown
- 2004-02-11 BR BRPI0407520-0A patent/BRPI0407520A/pt not_active Application Discontinuation
- 2004-02-11 PT PT04710031T patent/PT1597239E/pt unknown
- 2004-02-11 RU RU2005128774/04A patent/RU2376294C2/ru active
- 2004-02-11 DK DK04710031.8T patent/DK1597239T4/da active
- 2004-02-11 JP JP2005518421A patent/JP4456079B2/ja not_active Expired - Lifetime
- 2004-02-11 CN CNB2004800043815A patent/CN100506803C/zh not_active Expired - Lifetime
- 2004-02-11 AT AT04710031T patent/ATE408605T1/de active
-
2005
- 2005-07-28 IL IL169975A patent/IL169975A/en active IP Right Grant
- 2005-08-08 ZA ZA200506339A patent/ZA200506339B/en unknown
- 2005-08-10 HR HRP20050707AA patent/HRP20050707B1/hr not_active IP Right Cessation
- 2005-08-18 CO CO05082094A patent/CO5601019A2/es not_active Application Discontinuation
- 2005-08-25 NO NO20053953A patent/NO330781B1/no unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996030347A1 (en) * | 1995-03-30 | 1996-10-03 | Pfizer Inc. | Quinazoline derivatives |
WO1999055683A1 (en) * | 1998-04-29 | 1999-11-04 | Pfizer Products Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
EP1044969A2 (en) * | 1999-03-31 | 2000-10-18 | Pfizer Products Inc. | Processes and intermediates for preparing anti-cancer compounds |
WO2001034574A1 (en) * | 1999-11-11 | 2001-05-17 | Osi Pharmaceuticals, Inc. | Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20050707B1 (hr) | Polimorf od {6,7-bis(2-metoksi-etoksi)-kinazolin-4-il}-(3e) | |
AP1434A (en) | Stable polymorph of N-(3-Ethynylphenylamino) -6, 7-bis (2-methoxyethoxy) -4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof. | |
IL173348A0 (en) | Thienopyridine and furopyridine kinase inhibitors | |
UA84167C2 (ru) | Производные хиназолина как ингибиторы тирозинкиназы, способ их получения (варианты), фармацевтическая композиция на их основе | |
HK1087613A1 (en) | Quinazoline derivatives and their use in the treatment of cancer | |
YU84603A (sh) | Novi inhibitori tirozin kinaze | |
MXPA05005223A (es) | Diaminotriazoles utiles como inhibidores de proteinas cinasas. | |
TW200634012A (en) | 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | |
WO2006050109A3 (en) | Novel kinase inhibitors | |
PL406680A1 (pl) | Inhibitory kinaz tyrozynowych | |
ZA200702645B (en) | Diaminotriazole compounds useful as protein kinase inhibitors | |
TW200504015A (en) | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | |
HK1096673A1 (en) | Compositions useful as inhibitors of protein kinases | |
MY141739A (en) | Substituted quinazoline derivatives as inhibitors of aurora kinases | |
HK1065033A1 (en) | Thiazole compounds useful as inhibitors or proteinkinases | |
WO2004063151A3 (en) | Novel tyrosine kinase inhibitors | |
WO2004030620A3 (en) | Novel tyrosine kinase inhibitors | |
UA85394C2 (ru) | Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ | |
WO2007023115A3 (en) | P38 map kinase inhibitors and methods for using the same | |
BRPI0416030A (pt) | pirido-7-pirimidin-7-onas substituìdas com hidroxialquila | |
MXPA04004981A (es) | Derivados de piperazina para uso como antagonistas del receptor ccr-3 en tratamiento de asma. | |
ATE507218T1 (de) | Benzodiazepin-derivate als rock-kinasen hemmer | |
WO2005097755A3 (de) | Imidazolderivate als hemmer von tyrosinkinase | |
MXPA04005151A (es) | Compuestos terapeuticos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
B1PR | Patent granted | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20190129 Year of fee payment: 16 |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20200204 Year of fee payment: 17 |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20210202 Year of fee payment: 18 |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20220204 Year of fee payment: 19 |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20221229 Year of fee payment: 20 |
|
PB20 | Patent expired after termination of 20 years |
Effective date: 20240211 |